Does LENVATINIB Cause Malignant neoplasm progression? 2,929 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 2,929 reports of Malignant neoplasm progression have been filed in association with LENVATINIB (Lenvima). This represents 8.7% of all adverse event reports for LENVATINIB.
2,929
Reports of Malignant neoplasm progression with LENVATINIB
8.7%
of all LENVATINIB reports
1,549
Deaths
1,298
Hospitalizations
How Dangerous Is Malignant neoplasm progression From LENVATINIB?
Of the 2,929 reports, 1,549 (52.9%) resulted in death, 1,298 (44.3%) required hospitalization, and 143 (4.9%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LENVATINIB. However, 2,929 reports have been filed with the FAERS database.
What Other Side Effects Does LENVATINIB Cause?
Diarrhoea (4,262)
Hypertension (4,152)
Fatigue (3,603)
Decreased appetite (3,257)
Nausea (2,492)
Blood pressure increased (2,228)
Vomiting (1,962)
Asthenia (1,643)
Malaise (1,602)
Weight decreased (1,529)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
OSIMERTINIB (2,920)
Which LENVATINIB Alternatives Have Lower Malignant neoplasm progression Risk?
LENVATINIB vs LEPONEX
LENVATINIB vs LERCANIDIPINE
LENVATINIB vs LETAIRIS
LENVATINIB vs LETERMOVIR
LENVATINIB vs LETROZOLE